Additionally, repositioning calcium signaling-blocking drugs such as CCBs is a novel strategy for targeting IGF2 signaling to prevent both emphysema and lung cancer without the potential deleterious effects of metabolic disorders. This evidence concerns the gene IGF2 and metabolic disease.